Elevance Health Q3 2026 Earnings: The $6.99 Beat Built on a 90.6% Benefit Ratio

On October 21, 2026, Elevance Health (NYSE: ELV) reported third-quarter results the company called "ahead of expectations": operating revenue of $50.4 billion (+0.7%), diluted EPS of $6.27 (+17.9%) and adjusted diluted EPS of $6.99 (+15.9%), then raised full-year guidance to at least $22.00 GAAP and at least $29.00 adjusted. The beat has two authors, and the release names both: "improved operating performance and a net non-operating benefit of $1.85 per share." The operating half is a benefit expense ratio of 90.6%, down 70 basis points on better Medicare Advantage and Individual ACA performance. The non-operating half is net investment income of $1,037 million, up 65.9% year over year — a $412 million jump that more than accounts for the entire $388 million pre-tax income improvement, which means underwriting carried the ratio while the bond portfolio carried the dollars. This is the quarter a managed-care company beat on both sides of that split at once.

The Headline Numbers​

Elevance's fiscal year is the calendar year; Q3 2026 ended September 30, 2026. Every figure below comes from the Form 8-K and its earnings release (Exhibit 99.1), cross-checked against the Form 10-Q filed the same day, which carries the fully disaggregated balance sheet.

Read the table as a tug-of-war the bond portfolio won. Benefit expense fell $361 million while premiums were essentially flat — that is the 70-basis-point ratio improvement, the genuine operating win. But operating expense rose $480 million (+9.1%), so reportable operating gain actually fell 2.0% to $1,269 million. What turned a flat operating quarter into +27.6% pre-tax income is the $412 million jump in net investment income, partly offset by a tax bill that more than doubled — and the tax comp deserves a footnote: Q3 2025's effective rate was just 15.6%, while this quarter's 25.1% is the normal one, so last year flattered the comparison. Below the line, 6.1 million fewer diluted shares (−2.7%, the buyback at work) lifted EPS growth above net-income growth on both a GAAP and adjusted basis.

The GAAP-to-adjusted bridge, straight from the release's reconciliation:

Note what is absent: the $935 million CMS-notice accrual that dominates the nine-month numbers sits entirely outside this quarter — none of it is in Q3 operating expense. This bridge is the recurring cast of add-backs, and at $155 million net of tax it is actually $5 million smaller than last year's.

Revenue Deep Dive​

Elevance discloses four reportable segments, and the quarter's thesis is that the two Carelon services businesses are growing faster and earning more per dollar than the insurance risk pool they serve.

Health Benefits grew revenue 2.6% on what the release calls "higher premium yields and service fee revenue," but operating gain fell more than a quarter to $436 million — a 1.0% margin. The release attributes the decline to "targeted investments to support our long-term operating model," partly offset by the benefit-ratio improvement. With $43.4 billion of revenue earning $436 million, this segment now runs at roughly break-even on an operating basis; every dollar of its profit is a rounding error on its premium line, which is exactly why the benefit ratio, not revenue, is the number to watch here.

CarelonRx (the pharmacy benefit manager) is the profit engine in miniature: $616 million of operating gain on $11.6 billion of revenue, a 5.3% margin that widened 20 basis points. Carelon Services grew gain 33% to $292 million with margin up 80 basis points to 3.8%, on what the release calls "strong performance of Carelon Services risk-based solutions and the improved profitability of our specialty pharmacy." Together the two Carelon segments earned $908 million — more than twice Health Benefits' $436 million — on less than half its revenue. The strategy slide writes itself: risk business supplies the members, services businesses supply the margin.

Inside Health Benefits, the revenue mix tells the membership story in dollars:

Total medical membership fell 487 thousand year over year to 44.9 million — Medicaid, Medicare Advantage and Employer Group risk all shrank — yet every line except FEP grew revenue. That is the pricing thesis made visible: "higher premium yields" more than offset fewer members. The extreme case is Medicare: revenue up 0.8% while total Medicare membership fell 10.4% (Advantage alone collapsed 15.5%), which means per-member yield rose roughly 13% — rate increases and mix doing heavy lifting. Management's pricing language belongs to this table: in a managed-care company, "premium yields" is the selling-price theme, and this quarter it is confirmed by the ledger — revenue up, heads down, in nearly every risk pool.

The Margin Story​

(Annual ratios from the 10-Ks; benefit ratio is benefit expense ÷ premiums, operating-expense ratio is operating expense ÷ operating revenue, and operating margin is reportable operating gain ÷ operating revenue per the release's definition.)

The multi-year picture is a three-year underwriting squeeze that may have just turned. The benefit ratio deteriorated 300 basis points from FY2023 (87.0%) to FY2025 (90.0%) and kept climbing into Q3 2025 (91.3%) — medical costs outrunning premiums, the managed-care disease. This quarter's 90.6% is the first year-over-year improvement in that run, "driven by better performance in Medicare Advantage and Individual ACA compared to the prior year." Seventy basis points on $41.7 billion of quarterly premiums is roughly $290 million a quarter — over $1.1 billion annualized — the single most valuable number in the release if it holds.

The offset is the operating-expense ratio, which jumped 90 basis points to 11.4% (11.3% adjusted). The release says the increase "principally reflected targeted, one-time investments in capabilities that support our long-term performance, along with spending to advance business growth and quality initiatives." One-time is doing heavy lifting in that sentence — adjusted operating expense is still up 8.8% year over year after stripping the $68 million of named items — so the right reading is that Elevance spent most of its underwriting gain on growth and capability before it reached operating income. That is why GAAP operating margin ticked down (2.6% to 2.5%) while pre-tax margin jumped (2.8% to 3.5%): operations treaded water and investments did the rest.

The One Big Question: How Much of the $6.99 Is Repeatable?​

Decompose the $0.96 year-over-year adjusted-EPS improvement ($6.03 to $6.99) into its three authors. First, underwriting: the 70-basis-point benefit-ratio improvement on flat premiums is worth roughly $290 million pre-tax, or about $1.00 per share after tax — genuinely recurring if medical-cost trends stay tamed. Second, the share count: −2.7% of diluted shares mechanically adds about $0.17. Third, net investment income: +$412 million pre-tax, which at a normal tax rate is roughly $1.40 per share — but the release's own framing warns you off annualizing it, attributing $1.85 per share to "net non-operating benefit" and then defining the 2027 baseline to exclude "non-recurring net investment income and other non-operating items."

That baseline definition is the tell. Management guides 2027 to "at least 12% growth in adjusted diluted earnings per share" — but from "our higher earnings baseline of at least $26.75," not from the $29.00 full-year guide. The $2.25 gap between guide and baseline is management's own estimate of what does not repeat: one-time investment income and one-time spending. So the honest decomposition of the quarter is: about $1.00 of recurring underwriting improvement, partly reinvested through the operating-expense line, plus a large investment-income quarter that management itself refuses to project forward. The bull case is that the benefit ratio has turned and 2027 compounds off a clean $26.75. The bear case is that the ratio improvement is one quarter after twelve bad ones, and the EPS beat investors cheered was mostly the bond market.

The nine-month numbers sharpen the point. Nine-month net income is down 10.9% to $4,557 million because the first half carries the $935 million accrual for "certain historical Medicare Advantage risk adjustment data" under the February 2026 CMS notice — $4.28 per share, the company's "current best estimate of the identified potential exposure." Q3 is clean of it, but the exposure is an estimate, not a settlement; if CMS's final number exceeds $935 million, the true-up lands in a future quarter's operating expense. Watch the 10-K's contingencies note, not the press release, for that number.

Tracking a $127.8 Billion Balance Sheet in Plain Text​

A health insurer is a float business wearing a healthcare costume — premiums arrive before claims are paid, and the $18.4 billion medical-claims-payable reserve is the timing difference made visible — and modeling it in Beancount forces every dollar of that float to reconcile. Our open ledger reconstructs Elevance line by line from its own filings — read how we model every company for the shared conventions. Income is negative (credit), expenses positive (debit), and the transaction sums to zero:

; FY2026Q3 Income Statement — quarter ended September 30, 2026
; Check: −51429 + 37779 + 5640 + 5752 + 358 + 106 + 451 + 1343 = 0 ✓
 
2026-09-30 * "Elevance Health, Inc." "FY2026Q3 Income Statement"
  Income:Revenue                         -51429 MUSD  ; premiums 41,704 + product revenue 6,454 + service fees 2,282 + net investment income 1,037 − net losses on financial instruments 48
  Expenses:CostOfRevenue                    37779 MUSD  ; benefit expense (90.6% of premiums)
  Expenses:CostOfRevenue                     5640 MUSD  ; cost of products sold
  Expenses:SellingGeneralAdministrative      5752 MUSD  ; operating expense (11.4% of operating revenue; includes $68M of transaction/integration, optimization and litigation costs excluded from adjusted results)
  Expenses:Interest                            358 MUSD  ; interest expense
  Expenses:AmortizationOfAcquiredIntangibles    106 MUSD  ; amortization of other intangible assets
  Expenses:IncomeTax                          451 MUSD  ; income tax expense
  Equity:Adjustments                         1343 MUSD  ; net income offset (RE set by balance assertion)

The balance-sheet number that tells the narrative is $18,438 million of medical claims payable, up $1,354 million (+7.9%) since year-end while nine-month premiums were essentially flat. That reserve growing faster than the premium base is the mirror of the benefit-ratio story: Days in Claims Payable stretched to 44.9, up 3.5 days year over year, which means Elevance is holding providers' money longer — flattering operating cash flow ($7.5 billion over nine months, up 79%) while signaling that claims severity is not obviously retreating. The second tell sits in equity: accumulated other comprehensive loss nearly quadrupled to −$1,676 million on $1,221 million of nine-month unrealized investment losses, the same bond portfolio that produced the quarter's $1,037 million of investment income marking down the other side of the balance sheet. Watch DCP against the benefit ratio each quarter: if both improve together, the turn is real; if the ratio improves only because the reserve is stretching, it is timing, not underwriting.

The Multi-Year Arc​

(LTM = nine months 2026 plus Q4 2025, where Q4 2025 is the FY2025 annual less nine-month 2025 from the release: revenue $49,747 million, net income $546 million, benefit expense $38,065 million on premiums of $40,690 million. All exact differences of filed figures. The ledger itself starts at FY2024 — two audited annuals plus the current quarter — with FY2023 shown here from 10-K comparatives for context.)

The arc is revenue without profit growth: total revenue up 16% from FY2023 to FY2025 while net income fell 5.5%, because the benefit ratio ate 300 basis points faster than the operating-expense ratio gave back 120. Premiums did the revenue work (+14.2% in FY2025 alone on yields, not heads — membership has fallen two years running), and the tax line cushioned FY2025 with a 15.6% effective rate on a discrete restructuring benefit, without which net income would have fallen further. The LTM column looks worse than FY2025 on every margin because it carries the $935 million CMS accrual — strip that one item and LTM net income is roughly $5.8 billion after tax, the cleanest trailing number in the table. That is the bull case in one sentence: the revenue machine works, the tax and CMS items are noise, and if the benefit ratio has genuinely turned, operating leverage finally flows the right way. The bear case is the same table read left to right: three years of medical costs outrunning premiums is a trend, and one quarter of −70 basis points is a data point.

The Verdict: Bull vs. Bear​

Bull Case

• The benefit ratio turned: 90.6% is the first year-over-year improvement after a three-year climb, worth roughly $290 million a quarter — and it came from Medicare Advantage and Individual ACA, the two books investors feared most.
• Carelon is a second engine, not a sidecar: $908 million of quarterly operating gain at 4.7% blended margin, growing double digits while the risk business earns 1.0%.
• Pricing power is proven, not promised: revenue grew in every risk line except FEP while membership fell 487 thousand — yields, not heads, and Medicare yield rose roughly 13% per member.
• Capital returns compound the turn: 6.1 million fewer shares year over year, $330 million of Q3 buybacks at $398.75 with $5.0 billion authorized, and a $1.72 quarterly dividend — EPS grows even if net income merely holds.
• The 2027 setup is de-risked by construction: +12% guided off a $26.75 baseline that already excludes non-recurring investment income, so the target does not need the bond market to repeat Q3.

Bear Case

• One quarter does not make a trend: the benefit ratio improved 70 basis points after deteriorating 300 over three years, while Days in Claims Payable stretched 3.5 days — reserve timing could be flattering the ratio.
• The EPS beat was mostly non-operating: pre-tax income rose $388 million while net investment income rose $412 million and operating gain fell $26 million — underwriting treaded water.
• The operating-expense ratio jumped 90 basis points to 11.4% on "targeted, one-time investments" that recur every quarter they are targeted — adjusted operating expense still grew 8.8% after the add-backs.
• The $935 million CMS accrual is an estimate, not a settlement: if the final Medicare Advantage risk-adjustment exposure exceeds the "current best estimate," the true-up hits a future quarter.
• Membership is shrinking in every risk pool that matters: MA −15.5%, Medicaid −4.9%, Employer risk −6.9% — a yield story works until regulators or employers push back on rates.

Our Take: Buy the turn in the ratio, discount the beat in the EPS. The 70-basis-point benefit improvement on the two scariest books, plus Carelon's double-digit gain growth, is genuine operating progress — but $1.85 of the $6.99 is non-operating by the company's own admission, and management's $26.75 baseline tells you exactly how much of this quarter they would underwrite. At 12% growth off $26.75, 2027 earns roughly $30 — the question for the stock is what multiple a 2.5%-margin insurer with a possibly-turning cost trend deserves, and nothing in this quarter answers that. Watch Q4's benefit ratio and DCP together: a second straight improvement with stable days-payable confirms the turn; a reversal confirms the bears.